Develops a humanized anti-measles antibody and enhanced fusion-protein vaccine for prophylaxis, post-exposure treatment, and immunocompromised protection.
A computationally designed peptide ELIXIR selectively inhibits pathogenic cardiac late sodium current, preserving normal flow and reducing arrhythmia risk.
Peptide microarray identifies immunoreactive epitopes for high-specificity serodiagnosis of hemorrhagic fevers, distinguishing infection from vaccination.
